Practical aspects of using donepezil in the treatment of dementia

Chebotareva A.D.; Levin O.S.

doi:https://doi.org/10.17116/jnevro2020120091137

Close metadata

Recommended articles:

Cytokine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12

The main mechanisms of development of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18

Curcumin-induced increased retinal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25

Differential diagnosis of Alzheimer’s disease and vascular cognitive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35

A comprehensive study of Alzheimer’s disease biomarkers in plasma and cerebrospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53

Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60

Treatment features of patients with vascular cognitive impairments. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):69-76

Novel prospects for early diagnosis of cognitive impairment using Eye-tracking technology. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):13-20

Experience of using ribociclib in the therapy of metastatic breast cancer in a regional oncological dispensary. P.A. Herzen Journal of Oncology. 2025;(3):89-93

Potential and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medicine. 2025;(7):94-99

Abstract:

Donepezil is the most commonly used drug of the group of cholinesterase inhibitors. It is recommended for tretament of Alzheimer’s disease. Donepezil is also used to treat dementia in Lewy body disease, Parkinson’s disease with dementia, and vascular dementia. In Russia, donepezil is not used as often, which is facilitated by the concern of doctors about the possibility of serious side-effects. Clinical studies demonstrate the safety and good tolerability of donepezil. Our study included 62 patients with dementia due to various neurodegenerative diseases (Alzheimer’s disease, Lewy body disease, Parkinson’s disease with dementia). Thirty-seven patients (59.7%) started to receive donepezil. Side-effects, including bradycardia, hypertension, aggressive behavior, increased tremor, were observed in 7 patients (18.9%). There was no correlation between the development of side-effects and polymorphisms of the CYP2D6 and MDR1 genes.

Keywords:

donepezil

cholinesterase inhibitor

safety

dementia

Alzheimer’s disease

pharmacogenetics

CYP2D6

MDR1

Authors:

Chebotareva A.D.

Russian Medicl Academy of Continuing Professional Education

Levin O.S.

Russian Medical Academy of Continuous Professional Education

SPIN RSCI: 5342-1373
Scopus AuthorID: 57147160800
ORCID: 0000-0003-3872-5923

Received:

07.07.2020

Accepted:

14.07.2020

Close metadata

References:

English C. Donepezil 23 mg: is it more advantageous compared to the original? Mental Health Clinician. 2012;1(11):272-273. https://doi.org/10.9740/mhc.n106739
Mendes IT, Ruela ALM, Carvalho FC, Freitas JTJ, Bonfilio R, Pereira GR. Development and characterization of nanostructured lipid carrier-based gels for the transdermal delivery of donepezil. Colloids Surf B Biointerfaces. 2019 Feb 6;177:274-281. https://doi.org/10.1016/j.colsurfb.2019.02.007
AnjiReddy K, Karpagam S. Hyperbranched cellulose polyester of oral thin film and nanofiber for rapid release of donepezil; preparation and in vivo evaluation. Int J Biol Macromol. 2019 Mar 1;124:871-887. https://doi.org/10.1016/j.ijbiomac.2018.11.224
Espinoza LC, Silva-Abreu M, Clares B, Rodríguez-Lagunas MJ, Halbaut L, Cañas MA, Calpena AC. Formulation Strategies to Improve Nose-to-Brain Delivery of Donepezil. Pharmaceutics. 2019 Feb 1;11(2):43-47.. https://doi.org/10.3390/pharmaceutics11020064
Patil RP, Pawara DD, Gudewar CS, Tekade AR. Nanostructured cubosomes in an in situ nasal gel system: an alternative approach for the controlled delivery of donepezil HCl to brain. J Liposome Res. 2018 Dec 2:1-10. https://doi.org/10.1080/08982104.2018.1552703
Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry. 2004 Jul;19(7):624-633. https://doi.org/10.1002/gps.1133
Adlimoghaddam A, Neuendorff M, Roy B, Albensi BC. A review of clinical treatment considerations of donepezil in severe Alzheimer’s disease. CNS Neurosci Ther. 2018 Oct;24(10):876-888. https://doi.org/10.1111/cns.13035
Rogers SL, Doody R, Mohs R, Friedhoff LT. E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer’s disease: results of a 30 week phase III trial. Neurology. 1996;46:A217 S14.001 ARI 8. https://doi.org/10.1016/s0924-977x(97)88829-3
Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT. International Donepezil Study Group. The effects of donepezil in Alzheimer’s disease results from a multinational trial. Dementia and Geriatric Cognitive Disorders. 1999;10(3):237-244. https://doi.org/10.1159/000017126
Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, Nishimura T. E2020 Study Group. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease: a 24 week, multicenter, double blind, placebo controlled study in Japan. Dementia and Geriatric Cognitive Disorders. 2000;11:6:299-313. https://doi.org/10.1159/000017259
Engedal K, Soininen H, Verhey F, Waldemar G, Winblad B, Wimo A, Wetterholm A-L, Zhang R, Haglund A, Subbiah P, The Donepezil Nordic Study Group. Donepezil improved or stabilized cognition over one year in patients with mild and moderate Alzheimer’s disease. Journal of the European College of Neuropsychopharmacology. 2000;10:3:S368. https://doi.org/10.1016/s0924-977x(00)80492-7
Mohs R, Doody R, Morris J, Ieni J, Perdomo C, Pratt R. Donepezil preserves activities of daily living in Alzheimer’s disease patients: results from a one year placebo controlled functional survival study. Neurology. 2000;54(Suppl 3):A415. https://doi.org/10.1016/s0924-977x(99)80460-x
AD2000 Collaborative Group. Long term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double blind trial. Lancet. 2004;363:2105-2115. https://doi.org/10.1016/s0140-6736(04)16499-4
Barrett MJ, Cloud LJ, Shah H, Holloway KL. Therapeutic approaches to cholinergic deficiency in Lewy body diseases. Expert Rev Neurother. 2020 Jan;20(1):41-53. https://doi.org/10.1080/14737175.2020.1676152
Tahami Monfared AA, Meier G, Perry R, Joe D. Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review. Neurol Ther. 2019 Dec;8(2):289-305. https://doi.org/10.1007/s40120-019-00154-7
Ballesteros J, Güemes I, Ibarra N, Quemada JI. The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review. J Head Trauma Rehabil. 2008 May-Jun;23(3):171-180. https://doi.org/10.1097/01.htr.0000319935.99837.96
Jin BR, Liu HY. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis. Neural Regen Res. 2019 May;14(5):805-816. https://doi.org/10.4103/1673-5374.249228
Meng YH, Wang PP, Song YX, Wang JH. Cholinesterase inhibitors and memantine for Parkinson’s disease dementia and Lewy body dementia: A meta-analysis. Exp Ther Med. 2019 Mar;17(3):1611-1624. https://doi.org/10.3892/etm.2018.7129
Haake A, Nguyen K, Friedman L, Chakkamparambil B, Grossberg GT. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Saf. 2020 Feb;19(2):147-157. https://doi.org/10.1080/14740338.2020.1721456
Blanco-Silvente L, Castells X, Saez M, Barceló MA, Garre-Olmo J, Vilalta-Franch J, Capellà D. Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer’s disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients. Int J Neuropsychopharmacol. 2017;20(7):519-528. https://doi.org/10.1093/ijnp/pyx012
Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018 Jun 18;6:CD001190. https://doi.org/10.1002/14651858.cd001190
Grossberg GT, Tong G, Burke AD, Tariot PN. resent algorithms and future treatments for Alzheimer’s disease. J Alzheimers Dis. 2019;67(4):1157-1171. https://doi.org/10.3233/jad-180903
Shigeta M, Homma A. Donepezil for Alzheimer’s disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Reviews. 2001;7(4):353-368. https://doi.org/10.1111/j.1527-3458.2001.tb00204.x
Dooley M., Lamb H.M. Donepezil. A review of its use in Alzheimer’s disease. Drugs & Aging. 2000;16:199-226. https://doi.org/10.2165/00002512-200016030-00005
Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer’s disease. Br J Clin Pharmacol. 2004;58(Supp 1):1-8. https://doi.org/10.1111/j.1365-2125.2004.01848.x
Atri A. Current and future treatments in Alzheimer’s disease. Semin Neurol. 2019;39(2):227-240. https://doi.org/10.1055/s-0039-1678581
Pratt RD, Perdomo CA, Surick IW, Ieni JR. Donepezil: tolerability and safety in Alzheimer’s disease. Int J Clin Pract. 2002;56:710-717. https://doi.org/10.1016/s0924-977x(99)80461-1
Hong YJ, Han HJ, Youn YC, Park KW, Yang DW, Kim SY, Kim HJ, Ji Kim E, Lee J-H & on behalf of the ODESA study (Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23 mg). Safety and tolerability of donepezil 23mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial. Alzheimers Res Ther. 2019;11(1):37. https://doi.org/10.1186/s13195-019-0492-1
Relkin NR, Reichman WE, Orazem J, McRae T. A large community based, open-label trial of donepezil in the treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2003;16:15-24. https://doi.org/10.1159/000069988
Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD; Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61:479-486. https://doi.org/10.1212/01.wnl.0000078943.50032.fc
Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R; Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:2323-2330. https://doi.org/10.1161/01.str.0000091396.95360.e1
Isik AT, Yildiz GB, Bozoglu E, Yay A, Aydemir E. Cardiac safety of donepezil in elderly patients with Alzheimer disease. Intern Med. 2012;5(6):575-578. https://doi.org/10.2169/internalmedicine.51.6671
Vogel SM, Mican LM, Smith TL. Donepezil-induced QTc prolongation: a case report. Ment Health Clin. 2019;9(3):128-132. https://doi.org/10.9740/mhc.2019.05.128
Pourmand A, Shay C, Redha W, Aalam A, Mazer-Amirshahi M. Cholinergic symptoms and QTc prolongation following donepezil overdose. Am J Emerg Med. 2017;35(9):1386.e1-1386.e3. https://doi.org/10.1016/j.ajem.2017.06.044
Tanaka A, Koga S, Hiramatsu Y. Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes. Intern Med. 2009;48(14):1219-1223. https://doi.org/10.2169/internalmedicine.48.2181
Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001 Dec;49(12):1590-1599. https://doi.org/10.1111/j.1532-5415.2001.49266.x
Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study. Clin Ther. 2010;32(7):1234-1251. https://doi.org/10.1016/j.clinthera.2010.06.019
Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events meta-analysis of randomized controlled trials. J Am Geriatr Soc. 2011;59(6):1019-1031. https://doi.org/10.1111/j.1532-5415.2011.03450.x
Montero-Odasso M, Speechley M, Chertkow H, Sarquis-Adamson Y, Wells J, Borrie M, Vanderhaeghe L, Zou GY, Fraser S, Bherer L, Muir-Hunter SW. Donepezil for gait and falls in mild cognitive impairment: a randomized controlled trial. Eur J Neurol. 2018 Nov 22. https://doi.org/10.1111/ene.13872
Babai S, Auriche P, Le-Louët H. Comparison of adverse drug reactions with donepezil versus memantine: analysis of the French Pharmacovigilance Database. Therapie. 2010 May-Jun;65(3):255-259. https://doi.org/10.2515/therapie/2010008
Igeta H, Suzuki Y, Motegi T, Sasaki A, Yokoyama Y, Someya T. Deterioration in donepezil-induced PR prolongation after a coadministration of memantine in a patient with Alzheimer’s disease. Gen Hosp Psychiatry. 2013 Nov-Dec;35(6):680.e9-10. https://doi.org/10.1016/j.genhosppsych.2013.04.007
Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer’s disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012;33(2-3):164-173. https://doi.org/10.1159/000338236
Shepherd G, Klein-Schwartz W, Edwards R. Donepezil overdose: a tenfold dosing error. Ann Pharmacother. 1999 Jul-Aug;33(7-8):812-815. https://doi.org/10.1345/aph.18273
Pourmand A, Shay C, Redha W, Aalam A, Mazer-Amirshahi M. Cholinergic symptoms and QTc prolongation following donepezil overdose. Am J Emerg Med. 2017 Sep;35(9):1386.e1-1386.e3. https://doi.org/10.1016/j.ajem.2017.06.044
Pourmand A, Shay C, Redha W, Aalam A, Mazer-Amirshahi M. Cholinergic symptoms and QTc prolongation following donepezil overdose. Am J Emerg Med. 2017;35(9):1386.e1-1386.e3. https://doi.org/10.1016/j.ajem.2017.06.044
Thornton SL, Clark RF. Encephalopathy from unintentional donepezil and memantine ingestion. Pediatr Emerg Care. 2014 Sep;30(9):649-650. https://doi.org/10.1097/PEC.0000000000000216
Garlich FM, Balakrishnan K, Shah SK, Howland MA, Fong J, Nelson LS. Prolonged altered mental status and bradycardia following pediatric donepezil ingestion. Clin Toxicol (Phila). 2014 Apr;52(4):291-294. https://doi.org/10.3109/15563650.2014.900182